Hauck & Aufhäuser Privatbankiers KGaA disclosed Gerresheimer (ETR:GXI), upping its target price to 80.00EUR today
- Updated: October 8, 2016
In a report released on 10/09/2016 Hauck & Aufhäuser Privatbankiers KGaA increased the stock price target of Gerresheimer (ETR:GXI) to 80.00EUR reporting a possible upside of 0.09%.
Previously on 10/8/2016, Hauck & Aufhäuser Privatbankiers KGaA reported on Gerresheimer (ETR:GXI) increased the target price from 0.00EUR to 80.00EUR. At the time, this indicated a possible upside of 0.09%.
Just yesterday Gerresheimer (ETR:GXI) traded 0.00% even at 73.37EUR. Gerresheimer’s 50-day moving average is 0.00EUR and its 200-day moving average is 0.00EUR. The last closing price is up 0.00% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 0 shares of GXI traded hands, down from an average trading volume of 0
Recent Performance Chart
Gerresheimer has 52 week low of 0.00EUR and a 52 week high of 0.00EUR and has a market capitalization of 0 EUR.
Brief Synopsis On Gerresheimer (ETR:GXI)
Gerresheimer AG is a Germany-based company that operates in the pharmaceuticals and health care industry. It is structured in three business segments: Plastic and Devices, Primary Packaging Glass and Life Science Research. The Company produces pharmaceutical packaging products, as well as drug-delivery systems made out of glass and plastics or a combination of both. Its product portfolio includes insulin pens, inhalers, pre-fillable syringes, vials, ampoules, bottles and containers for liquid and solid pharmaceuticals with closure and safety systems, plus cosmetic packaging products. The Company operates approximately 40 production facilities in Europe, North America, South America and Asia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.